Get the Stockscreener App
4.66
4.25%
0.19
After Hours:
4.62
-0.04
-0.86%
Qualigen Therapeutics Inc stock is traded at $4.66, with a volume of 33,261.
It is up +4.25% in the last 24 hours and down -23.29% over the past month.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
See More
Previous Close:
$4.47
Open:
$4.44
24h Volume:
33,261
Relative Volume:
0.43
Market Cap:
$3.28M
Revenue:
$4.79M
Net Income/Loss:
$-13.42M
P/E Ratio:
-1.1592
EPS:
-4.02
Net Cash Flow:
$-10.30M
1W Performance:
+20.41%
1M Performance:
-23.29%
6M Performance:
-69.44%
1Y Performance:
-86.31%
1-Day Range:
$4.33
$4.71
1-Week Range:
$3.8154
$5.05
52-Week Range:
$3.3358
$39.13
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
Name
Qualigen Therapeutics Inc
Sector
Industry
Phone
(760) 918-9165
Address
2042 CORTE DEL NOGAL, CALIFORNIA
Compare QLGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QLGN
Qualigen Therapeutics Inc
|
4.66 | 3.28M | 4.79M | -13.42M | -10.30M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Qualigen Therapeutics Inc Stock (QLGN) Latest News
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - GlobeNewswire Inc.
Qualigen Therapeutics, Inc. announced that it expects to receive $5.1 million in funding - Marketscreener.com
Qualigen Therapeutics secures $4.5 million in funding By Investing.com - Investing.com South Africa
Qualigen Therapeutics secures $4.5 million in funding - Investing.com India
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - The Manila Times
Qualigen Therapeutics (NASDAQ:QLGN) versus Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Review - Defense World
Qualigen Therapeutics Inc (QLGN) Quarterly 10-Q Report - Quartzy
Qualigen Therapeutics appoints new board member - Investing.com
Qualigen Therapeutics appoints new board member By Investing.com - Investing.com Canada
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com Canada
Qualigen Therapeutics announces 1-for-50 reverse stock split - Investing.com India
Qualigen Therapeutics announces 1-for-50 reverse stock split By Investing.com - Investing.com UK
Qualigen Therapeutics (STU:7R90) Enterprise Value : €4.58 Mil (As of Nov. 07, 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Operating Cash Flow per Sh - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Shares Outstanding (EOP) : 0.19 Mil (As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Long-Term Debt & Capital L - GuruFocus.com
Qualigen Therapeutics (STU:7R90) EV-to-Revenue : (As of Nov. 07, 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Cash Flow from Financing : €1.51 Mil (TTM As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Qualigen Therapeutics, Inc. Announces Appointment of Amy Broidrick as Executive Vice President and Chief Strategy Officer - Marketscreener.com
QLGN stock touches 52-week high at $5.05 amid market fluctuations - Investing.com
Qualigen Therapeutics Stock to Reverse Split on Tuesday, November 5th (NASDAQ:QLGN) - Defense World
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewswire
Qualigen Therapeutics Announces 1-for-50 Reverse Stock Split - TipRanks
Would I Buy Qualigen Therapeutics Inc (NASDAQ: QLGN) Stock At Any Time In The Future? - Stocks Register
Qualigen Therapeutics announces results of annual stockholder meeting By Investing.com - Investing.com Australia
Qualigen Therapeutics announces results of annual stockholder meeting - Investing.com India
Qualigen Therapeutics (STU:7R9) Enterprise Value : €4.47 Mil (As of Oct. 26, 2024) - GuruFocus.com
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - openPR
QLGN stock touches 52-week low at $0.11 amid market challenges - Investing.com India
Qualigen Therapeutics faces Nasdaq delisting notice By Investing.com - Investing.com Canada
Qualigen Therapeutics faces Nasdaq delisting notice - Investing.com India
Qualigen Therapeutics (NASDAQ:QLGN) Shares Up 4.4% – Here’s Why - Defense World
Qualigen Therapeutics appoints new director and audit chair By Investing.com - Investing.com South Africa
Qualigen Therapeutics appoints new director and audit chair - Investing.com India
Qualigen Therapeutics sees major executive reshuffle By Investing.com - Investing.com Canada
Qualigen Therapeutics, Inc. Announces management changes. - The Manila Times
Qualigen Therapeutics appoints new leadership amid strategic shift By Investing.com - Investing.com South Africa
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Sees Large Decline in Short Interest - Defense World
Qualigen Therapeutics sees major executive reshuffle - Investing.com
Qualigen Therapeutics appoints new leadership amid strategic shift - Investing.com
Qualigen Therapeutics Announces Executive Shakeup and Board Revamp - TipRanks
Qualigen Therapeutics Inc Stock (QLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):